InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,728.80
(
0.41%
)
US TECH 100
19,528.00
(
0.90%
)
Dow Jones
42,052.19
(
0.69%
)
Brent Oil
72.91
(
0.00%
)
Bitcoin
68,642.26
(
-0.96%
)
Post# of 253510
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120661
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 89620

Monday, 01/25/2010 11:23:11 PM

Monday, January 25, 2010 11:23:11 PM

Post# of 253510
I’m looking forward to hearing about ACHN’s HCV program whose compounds have an MoA so novel that the MoA couldn’t be disclosed. I think management’s handling of investor expectations with respect to this program has been silly, and this has (IMO) lowered management’s credibility, which wasn’t that high to begin with.

From today’s PR:

…the Company will provide an update on partnering efforts related to its non-HCV assets, elvucitabine and ACH-702.

If the update is that ACHN plans to spend even a dime of its own money on these programs, that would be bearish, IMO.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up